| Literature DB >> 26176860 |
Thomas J Crowley1, Manish S Dalwani1, Susan K Mikulich-Gilbertson1, Susan E Young1, Joseph T Sakai1, Kristen M Raymond1, Shannon K McWilliams1, Melissa J Roark1, Marie T Banich2.
Abstract
BACKGROUND: Accidental injury and homicide, relatively common among adolescents, often follow risky behaviors; those are done more by boys and by adolescents with greater behavioral disinhibition (BD). HYPOTHESIS: Neural processing during adolescents' risky decision-making will differ in youths with greater BD severity, and in males vs. females, both before cautious behaviors and before risky behaviors. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2015 PMID: 26176860 PMCID: PMC4503769 DOI: 10.1371/journal.pone.0132322
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Game; Participants' Behavioral Disinhibition Scores.
(a) Colorado Balloon Game. A: Decision Trial begins, yellow illuminated 4 sec. B: Chosen press executed during 0.5-second green light. Next, red light signals outcome, 3.5 sec. If left press in B, then C (counter increases 1 cent, dull sound, no change in balloon). If right press in B, then either D (counter decreases 10 cents, frowney face, popping sound, balloon shrinks), or E (counter increases 5 cents, smiley face, coin-drop sound, balloon puffs up). F: Fixation screen 2–4 sec. G: Directed Trial begins with 4-sec yellow half-light. Illuminated side (left here) indicates side to press when light turns green. Counter: current earnings. Then, the B-F sequence from the paired Decision Trial follows exactly, but participant knows that "the computer is playing the game now", and that only the counter increase of 2 cents upon the directed press affects participant. (b) 81 Participants’ BD Scores. Crosses: means, standard deviations.
Individual Participants' Medications.
| Group | Females | Males |
|---|---|---|
| Patient | Bupropion, ziprasidone | Amphetamine |
| Patient | Citalopram, lamotrigine | Fexofenadine |
| Patient | Oxcarbazepine, levonorgestrel | Fluoxetine, quetiapine |
| Patient | Bupropion | Unidentified ‘‘ulcer drug" |
| Patient | Fluoxetine | Methylphenidate |
| Patient | Aripiprazole | Unidentified "asthma inhaler" |
| Patient | Unidentified common-cold remedy | |
| Patient | Aripiprazole | |
| Comparison | Fluoxetine | Topiramate |
| Comparison | Lansoprazole, Spironolactone | Albuterol inhaler |
| Comparison | Ibuprofen | Amphetamine |
| Comparison | Unidentified "birth control" | Amphetamine |
| Comparison | Unidentified "birth control" |
Footnote:
+ indicates a combination medication
Demographic and Clinical Information.
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
| |
| Mean Age (SD) | 16.7 (1.1) | 16.5 (1.6) | 16.2 (1.1) | 16.5 (1.0) | NS | NS | NS | |||
| Behavioral Disinhibition Score: Mean (SD) | -0.49 (0.40) | -0.08 (0.69) | 3.9 (2.0) | 3.4 (1.3) | F(1,42.9) = 199.3 | 0.0005 | NS | NS | ||
| Socio-economic Status Score: Mean (SD) | 34.9 (15.7) | 34.5 (15.5) | 46.6 (13.3) | 47.2 (18.3) | F(1,73) = 11.4 | 0.001 | NS | NS | ||
| Eysenck Impulsiveness Score: Mean (SD) | 5.0 (3.7) | 6.7 (4.5) | 15.9 (5.0) | 11.9 (6.0) | NA | NA | F(1,77) = 6.94 | 0.010 | ||
| Youth Self Report: Conduct Problems Score: Mean (SD) | 2.2 (2.0) | 3.2 (2.4) | 9.9 (4.9) | 10.8 (4.2) | F(1,55.9) = 93.2 | 0.0005 | NS | NS | ||
| Conduct Disorder Lifetime Symptom count: Mean (SD) | 0.35 (0.59) | 0.45 (0.60) | 5.4 (3.3) | 6.8 (2.3) | F(1,39.2) = 160.7 | 0.0005 | NS | NS | ||
| CBCL | 1.4 (1.9) | 4.1 (3.6) | 7.8 (4.6) | 6.6 (4.6) | NA | NA | F(1,63.0) = 5.30 | 0.025 | ||
| CBCL | 1.7 (1.4) | 1.9 (3.7) | 7.0 (3.5) | 4.7 (4.6) | F(1,57.8) = 27.7 | 0.0005 | NS | NS | ||
| IQ Full-Scale score estimate: Mean (SD) | 103.5 (10.4) | 104.9 (9.0) | 95.4 (9.9) | 97.3 (8.9) | F(1,77) = 13.5 | 0.0005 | NS | NS | ||
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
| |||||
| Ethnicity: Non-Hispanic Euro-American (n) | 13 | 15 | 14 | 12 |
| NS | ||||
| Ethnicity: Other racial-ethnic groups (n) | 7 | 5 | 7 | 8 |
| NS | ||||
| Aggression Score | 0 (0) | 0.0 (0–4) | 6.0 (0–9) | 7.0 (0–9) | K-W | 0.0005 | ||||
| Conduct Disorder Lifetime Diagnosis (n) | 1 | 1 | 16 | 19 | x Sq (3) = 54.2 | 0.0005 | ||||
| Carroll Depression Rating Score | 3.0 (0–11) | 3.0 (0–15) | 9.0 (3–22) | 7.0 (0–28) | K-W | 0.0005 | ||||
| Substance Dep Symptoms, Across Drug | 0.0 (0–5) | 0.0 (0–3) | 11.0 (0–30) | 11.0 (1–31) | K-W | 0.0005 | ||||
| Recent Regular Smokers (n) | 1 | 1 | 20 | 6 |
| 0.0005 | ||||
| Tobacco Dependence (n) | 1 | 1 | 11 | 13 |
| 0.0005 | ||||
| Alcohol Abuse (n) | 0 | 0 | 4 | 8 | FE = 16.0 | 0.0005 | ||||
| Alcohol Dependence (n) | 0 | 0 | 14 | 8 |
| 0.0005 | ||||
| Cannabis Abuse (n) | 0 | 0 | 7 | 7 | FE = 17.1 | 0.0005 | ||||
| Cannabis Dependence (n) | 0 | 0 | 12 | 10 |
| 0.0005 | ||||
| Participants with Other Substance Use Disorders (n) | 0 | 0 | 11 | 9 | FE = 28.3 | 0.0005 | ||||
| Lifetime Court Appearances | 0 (0) | 0 (0) | 5.0 (0–28) | 9.0 (1–50) | K-W | 0.0005 | ||||
| Lifetime Admissions to Detention or Jail | 0 (0) | 0 (0) | 1.0 (0–6) | 2.0 (0–20) | K-W | 0.0005 | ||||
| Days on Probation, Last 6 Months | 0 (0) | 0 (0) | 0.0 (0–180) | 180 (0–180) | K-W | 0.0005 | ||||
Abbreviations:
ANOVA, analysis of variance. CBCL, Child Behavior Checklist. Cmp, Comparison. Dep, dependence. FE, Fisher exact test. K-W X Sq, Kruskall-Wallis Chi-square. n, number. NA, not assessed. NS, not significant. Pt, patient. SD, standard deviation. SES, socioeconomic status. X Sq, Pearson Chi-square.
Footnotes:
1Not provided if test is NS.
2If interactions/overall test was significant, 4 post-hoc comparisons, as shown by arrows: Cmp Male ←→ Pt Male Cmp Female ←→ Pt Female
3NS: p > 0.05, two-tailed. NA: Not assessed because of significant interaction.
4Highest class = V. Comparison mean score falls in Class IV, patient in Class III.
5n = 18.
6In one patient with no CBCL, YSR score was substituted for CBCL.
7Median (range) provided for very skewed values.
8"Regular" is at least monthly. All patient males had been regular smokers, but 14 were now in a smoke-free residential treatment facility.
9DSM-IV abuse or dependence on any drug not listed above.
w-yWithin one row values sharing a superscript are significantly different.
Participants' Behavior in Task.
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
| ||
| Happy, Balloon Puffs Up, Decision Trial | 14.7 (11.8) | 14.4 (16.8) | 17.1 (16.4) | 24.0 (18.2) | ANOVA | NS | NS | NS | |||
| Happy, Balloon Pops, Decision Trial | 75.6 (16.4) | 69.1 (25.8) | 68.2 (19.3) | 61.7 (16.2) | ANOVA | NS | NS | NS | |||
| Happy, Balloon Puffs Up, Directed Trial | 37.9 (15.8) | 40.3 (17.6) | 34.6 (20.6) | 34.8 (18.7) | ANOVA | NS | NS | NS | |||
| Happy, Balloon Pops, Directed Trial | 49.0 (12.2) | 45.7 (13.9) | 39.8 (21.0) | 42.8 (21.1) | ANOVA | NS | NS | NS | |||
| Total Risky Responses | 46.5 (9.9) | 52.4 (8.7) | 41.4 (15.0) | 52.2 (10.3) | ANOVA | NS | F(1,77) = 11.1 | 0.001 | NS | ||
| Total Cautious Responses | 41.5 (10.0) | 36.2 (9.1) | 44.5 (15.1) | 35.4 (9.4) | ANOVA | NS | F(1,77) = 8.43 | 0.005 | NS | ||
| Risky Wins | 25.9 (5.4) | 29.9 (4.6) | 23.3 (8.0) | 28.3 (5.2) | ANOVA | NS | F(1,77) = 11.4 | 0.001 | NS | ||
| Risky Losses | 20.6 (5.1) | 22.5 (4.8) | 18.1 (7.6) | 23.8 (6.0) | ANOVA | NS | F(1,69.4) = 8.40 | 0.005 | NS | ||
| Total $ Earnings in Game | 6.40 (0.43) | 6.37 (0.43) | 6.51 (0.61) | 6.13 (0.53) | ANOVA | NS | NS | NS | |||
| Decision Trial, Risky Response Time | 292.5(28.2) | 252.5 (27.3) | 276.6 (24.9) | 263.9 (27.4) | ANOVA | NA | NA | F(1,77) = 5.23 | 0.025 | ||
| Decision Trial, Cautious Response Time | 279.7(26.1) | 254.7 (29.9) | 287.2 (30.4) | 258.7 (31.1) | ANOVA | NS | F(1,77) = 16.7 | 0.001 | NS | ||
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
| ||||||
| Who told me which to press, Decision Trial | 3.0 (0–54.5) | 1.0 (0–64) | 2.0 (0–29.4) | 2.0 (0–65) | K-W |
| NS | ||||
| Who told me which to press, Directed Trial | 97.5 (35–100) | 99.0 (1–100) | 94.6 (1–100) | 98.3 (56–100) | K-W |
| NS | ||||
| Total Missed Responses | 3.5 (0–15) | 1.0 (0–5) | 7.0 (2–30) | 2.0 (0–6) | K-W |
| 0.0005 | ||||
Abbreviations: As in Table 2.
Footnotes:
1Mean (Standard Deviation).
2"Really, really happy" = 0 mm; "Really, really sad" = 100 mm.
3Based on completed responses.
4"I told myself" = 0 mm; "the computer told me" = 100 mm.
5Median (Range) provided for very skewed values.
6If interactions/overall test was significant, 4 post-hoc comparisons, as shown by arrows: Cmp Male ←→ Pt Male Cmp Female ←→ Pt Female
w-zWithin one row values sharing a superscript are significantly different.
Fig 2Decline in risky presses as probability of loss increased.
Four groups: patient males, comparison males, patient females, comparison females. Raw (not fitted) data shown. Comparison males' error bars: red to reduce confusing overlaps. Trials required a choice: a cautious response earned 1 cent; a risky response either won 5 or lost 10 cents. Probability of winning after risky choices declined from 0.78 to 0.22 as game progressed.
Fig 3Cortical regions near scalp where groups' activations differed significantly.
These regions are potentially accessible to transcranial direct current stimulation. Row labels: Cau, before cautious responses. Ris, before risky responses. Cmp, comparison participants. F, females. M, males. Pt, patients. Three rows of possible activations not shown: (a) Cau: Pt>Cmp and (b) Ris: Pt>Cmp, were both devoid of activation; (c) Cau: F>M had activation only at site marked by Green pointer tip in Ris: M>F. Significant t-values range from 2.64 (dark red) to 7.76 (white); details in Tables 4 and 5.
The Groups' Activity Differences before Cautious Responses.
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
| Sup Fr Gy | R8,10 | 1451 | 24 | 56 | 14 | 3.7 | dlPFC, Fr Pole | Med Fr Gy | R8 | 99 | 12 | 18 | 52 | 3.7 | mPFC |
| Mid Fr Gy | R6,8,9,10 | 26 | 18 | 40 | 5.2 | dlPFC, Fr Pole | Sup Fr Gy | R8 | 10 | 18 | 54 | 3.4 | mPFC | ||
| Med Fr Gy | R9 | 26 | 36 | 30 | 3.0 | mPFC | Cing Gy | R32 | 12 | 20 | 46 | 2.7 | mPFC | ||
| Med Fr Gy | R,L10,32 | 198 | 10 | 48 | 4 | 3.3 | mPFC |
|
| ||||||
| Ant Cing Gy | R,L32 | 0 | 52 | 12 | 3.3 | mPFC | |||||||||
| Sup Fr Gy | L10 | 193 | -40 | 50 | 30 | 4.1 | Fr Pole |
| |||||||
| Mid Fr Gy | L9,10 | -40 | 44 | 30 | 3.0 | dlPFC |
|
|
|
|
|
|
|
| |
| Med Fr Gy | R,L9. L8 | 1948 | -12 | 40 | 24 | 4.2 | mPFC |
|
|
| |||||
| Ant Cing Gy | R,L24,32 | -12 | 28 | 28 | 6.6 | mPFC | Sup Fr Gy | R,L10 | 3300 | 24 | 60 | 2 | 2.9 | Fr Pole | |
| Cing Gy | R,L32 | -4 | 14 | 44 | 3.5 | mPFC | Mid Fr Gy | R,L10 | 34 | 54 | 6 | 3.5 | Fr Pole | ||
| Sup Fr Gy | L6,8 | -12 | 12 | 56 | 3.4 | mPFC, SMA | Med Fr Gy | R,L10,32 | 20 | 52 | 0 | 2.7 | mPFC | ||
| Inf Fr Gy | R47 | 1057 | 34 | 20 | -16 | 5.4 | vlPFC | Ant Cing Gy | R,L25 | -14 | 32 | -4 | 2.8 | mPFC | |
| Sup Temp Gy | R22,38 | 44 | 12 | -14 | 2.9 | Temp | Claustrum | R | 28 | 10 | 12 | 2.8 | Sens Integ | ||
| Insula | R13 | 40 | 8 | -2 | 3.7 | Insula | Caudate | R,L | 8 | 10 | 2 | 3 | Striatum | ||
| Mid Fr Gy | L11,47 | 5238 | -38 | 34 | -4 | 4.1 | OFC, vlPFC | Putamen | R,L | 20 | 6 | 2 | 3.0 | Striatum | |
| Inf Fr Gy | L45,47 | -36 | 28 | -8 | 7.0 | vlPFC | Glob Pall | R,L | 18 | -2 | 4 | 2.9 | Striatum | ||
| Sup Temp Gy | L22,38 | -44 | 12 | -16 | 3.2 | Temp | Thal | R,L | -14 | -4 | 6 | 4.2 | Thal | ||
| Subcall Gy | R25 | 12 | 10 | -14 | 2.7 | mPFC | Mid Fr Gy | R9 | 187 | 24 | 28 | 32 | 4.4 | dlPFC | |
| Ant Cing Gy | R,L25 | 6 | 10 | -8 | 3.6 | mPFC | Inf Par Lob | R40 | 229 | 50 | -44 | 26 | 2.9 | Par | |
| Caudate | R | 6 | 8 | 2 | 3.2 | Striatum | Supramarg Gy | R40 | 52 | -48 | 32 | 3.3 | Par | ||
| Putamen | R,L | -20 | 6 | -4 | 3.4 | Striatum | Nodule | R,L | 178 | 14 | -44 | -36 | 3.4 | Cerebell | |
| Hypothal | R,L | 4 | -2 | -8 | 4.6 | Limbic | Pons | R | 14 | -42 | -40 | 2.8 | Br Stem | ||
| Globus Pall | R,L | -18 | -6 | -6 | 3.1 | Striatum | Uvula | R,L | -12 | -62 | -38 | 3.1 | Cerebell | ||
| Subthal Nucl | R,L | 10 | -12 | -4 | 3.1 | Basal Ganglia | Pyramis | L | -16 | -64 | -38 | 2.8 | Cerebell | ||
| Insula | L13 | -40 | -14 | -4 | 3.1 | Insula |
|
| |||||||
| Thal | R,L | -6 | -20 | 2 | 3.8 | Thal | |||||||||
| Red Nucl | R,L | 4 | -20 | -10 | 3.0 | Br Stem |
| ||||||||
| Parahip Gy | L28 | -24 | -24 | -12 | 3.2 | Limbic |
|
|
|
|
|
|
|
| |
| Claustrum | L | -32 | -24 | 6 | 3.1 | Sens Integ |
|
|
| ||||||
| Hippoc | L | -30 | -26 | -10 | 2.7 | Limbic | Precent Gy | R4 | 109 | 16 | -32 | 58 | 3.8 | Motor | |
| Mid Br | R,L | -6 | -28 | -4 | 4.1 | Mid Br | Postcent Gy | R3 | 26 | -32 | 62 | 2.7 | Motor | ||
| Mid Temp Gy | L21,22 | -50 | -38 | -2 | 3.5 | Temp | Paracent Lob | R6 | 12 | -32 | 58 | 3.3 | Motor, Sens | ||
| Cing Gy | L31 | 255 | -10 | -24 | 32 | 3.7 | Limbic |
|
| ||||||
| Paracent Lob | L31 | -2 | -24 | 46 | 2.7 | Motor, Sens | |||||||||
| Mid Temp Gy | R21,22 | 365 | 46 | -26 | -8 | 4.0 | Temp | ||||||||
| Sup Temp Gy | R22 | 48 | -26 | -2 | 3.4 | Temp | |||||||||
| Supramarg Gy | L40 | 152 | -54 | -42 | 36 | 3.9 | Parietal | ||||||||
| Inf Par Lob | L40 | -52 | -42 | 40 | 3.3 | Parietal | |||||||||
| Paracent Lob | L5 | 102 | -6 | -44 | 52 | 3.5 | Motor, sens | ||||||||
| Precuneus | L7 | -6 | -48 | 48 | 2.7 | Med Par | |||||||||
| Cing Gy | R31 | 186 | 18 | -40 | 36 | 4.0 | Limbic | ||||||||
| Precuneus | R7,31 | 16 | -48 | 34 | 2.7 | Med Par | |||||||||
| Lingual Gy | L19 | 116 | -30 | -58 | -6 | 4.0 | Occip | ||||||||
| Parahip Gy | L19 | -26 | -54 | -10 | 2.7 | Limbic | |||||||||
| Precuneus | L7,31 | 140 | -16 | -74 | 28 | 4.4. | Parietal | ||||||||
| Cuneus | L18 | -18 | -78 | 22 | 2.7 | Occip | |||||||||
| Cuneus | R7,18,19 | 129 | 6 | -82 | 26 | 3.2 | Occip | ||||||||
| Precuneus | R7,31 | 10 | -68 | 30 | 3.1 | Med Par | |||||||||
|
|
| ||||||||||||||
Abbreviations (Tables 4 and 5):
Ant, anterior. Br, brain. Cerebell, cerebellum. Cing, cingulate. Cmp, comparison participants. dl, dorsolateral. Fr, frontal. Glob Pall, globus pallidus. Gy, gyrus. Hippoc, hippocampus. Hypothal, hypothalamus. Inf, inferior. L, left. Lob, lobule. m or Med, medial. Nucl, nucleus. Pt, patients. Occip, occipital. OFC, orbitofrontal cortex. Par, parietal. Paracent, paracentral. Parahip, parahippocampal. PFC, prefrontal cortex. Postcent, postcentral. Precent, precentral. R, right. Sens, sensory. Sens Integ, sensory integration. SMA, supplementary motor area. Subcall, subcallosal. Subthal, subthalamic. Sup, superior. Supramarg, supramarginal. Temp, temporal. Thal, thalamus. vl, ventrolateral.
Footnotes (Tables 4 and 5):
aContrast: [(Decision Trial - Directed Trial)Group 1 - (Decision Trial - Directed Trial)Group 2]. Cluster-level family-wise error correction (pcorr < 0.05).
bIf bilateral, the larger maximum is shown.
cTotal voxels in each cluster. A structure with a number here, and the following structures without numbers, comprise one cluster.
dMaximally activated voxel in region.
The Groups' Activity Differences before Risky Responses.
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
| Sup Fr Gy | R10 | 115 | 22 | 46 | 24 | 3.9 | Fr Pole | Inf Fr Gy | L47 | 243 | -38 | 14 | -16 | 4.4 | vlPFC |
| Mid Fr Gy | L47 | 697 | -34 | 38 | -4 | 4.0 | vlPFC | Insula | L13 | -34 | 12 | -16 | 3.3 | Insula | |
| Inf Fr Gy | L47 | -34 | 32 | -1 | 7.8 | vlPFC | Sup Temp Gy | L38 | -46 | 16 | -20 | 3.1 | Temp | ||
| Inf Fr Gy | R47 | 295 | 34 | 32 | 0 | 3.7 | vlPFC | Mid Temp Gy | R21 | 198 | 50 | -22 | -12 | 4.3 | Temp |
| Ant Cing Gy | L24,32 | 778 | -14 | 32 | 28 | 5.5 | mPFC | Mid Temp Gy | R22 | 164 | 52 | -36 | 4 | 3.3 | Temp |
| Med Fr Gy | L8,32,6,9 | -14 | 30 | 38 | 4.2 | m & dlPFC | Sup Temp Gy | R22 | 54 | -42 | 6 | 3.0 | Temp | ||
| Cing Gy | L32 | -12 | 22 | 36 | 2.8 | mPFC | Supramarg Gy | R40 | 273 | 58 | -50 | 26 | 4.0 | Par | |
| Sup Fr Gy | L6 | -14 | 20 | 50 | 2.8 | SMA | Inf Par Lob | R40 | 46 | -50 | 42 | 2.8 | mPar | ||
|
|
| Mid Occ Gy | R18 | 184 | 32 | -64 | 0 | 3.7 | Occ | ||||||
| Cuneus | R17 | 26 | -84 | 8 | 2.7 | Occ | |||||||||
|
|
| ||||||||||||||
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
| Sup Fr Gy | L8 | 164 | -16 | 46 | 52 | 4.7 | dlPFC | Med Fr Gy | R10 | 115 | 20 | 56 | 8 | 3.7 | Fr Pole |
| Sup Fr Gy | R6,8 | 901 | 12 | 16 | 54 | 6.0 | SMA, mPFC | Sup Fr Gy | R10 | 20 | 50 | 18 | 2.7 | Fr Pole | |
| Med Fr Gy | R6,8,9,32 | 10 | 12 | 50 | 3.3 | m & dlPFC | Lingual | R | 832 | 2 | -48 | -24 | 3.1 | Cerebell | |
| Cing Gy | R24,32 | 16 | 22 | 36 | 3.4 | mPFC | Culmen | R | 10 | -52 | -22 | 3.1 | Cerebell | ||
| Mid Fr Gy | R6 | 24 | 14 | 58 | 2.8 | SMA | Fastigium | R | 10 | -54 | -28 | 3.2 | Cerebell | ||
| Insula | L13 | 291 | -38 | 12 | -10 | 4.1 | Insula | Dentate | R | 14 | -58 | -32 | 3.2 | Cerebell | |
| Inf Fr Gy | L47 | -28 | 16 | -16 | 3.3 | vlPFC | Tonsil | R | 8 | -60 | -40 | 3.4 | Cerebell | ||
| Claustrum | L | -28 | 18 | 0 | 3.1 | Sens Integ | Declive | R | 8 | -62 | -22 | 3.1 | Cerebell | ||
| Lingual Gy | L19 | 113 | -14 | -48 | -4 | 3.9 | Occip | Nodule | R | 8 | -64 | -34 | 4.7 | Cerebell | |
| Parahip Gy | L30 | -16 | -46 | 0 | 3.1 | Temp | Pyramis | R | 24 | -66 | -38 | 3.0 | Cerebell | ||
| Culmen | L | -12 | -46 | -6 | 3.5 | Cerebell | Uvula | R | 6 | -66 | -38 | 3.1 | Cerebell | ||
| Cing Gy | L31 | 180 | -6 | -50 | 28 | 3.5 | mPar |
| 947 | ||||||
| Precuneus | L31 | -10 | -54 | 32 | 2.8 | mPar | |||||||||
| Post Cing | L23,30 | -4 | -50 | 22 | 2.7 | mPar | |||||||||
|
|
| ||||||||||||||
Abbreviations, Footnotes: As in Table 4.
Fig 4Three brain regions showing significant male:female x comparison:patient group interactions (cf., Tables 4 and 5).
Dashed lines, males. Solid lines, females. Cmp, comparison participants. Pt, patients. Activation intensity is the mean activation difference (Decision Trial – Directed Trial) for all voxels in the cluster, so negative values indicate relative deactivation in Decision Trials, compared to Directed Trials. Standard errors of the means for each of these points lie in the narrow range ± 0.064–0.094.
Fig 5Assessing possible confounds by changing samples or procedures.
Clusters activating significantly differently in groups appear as shadows on a 2-dimensional surface; activations preceding cautious or risky behaviors are shown separately. Abbreviations: Cmp, comparison participants. F, females. M, males. Pt, patients. Row A: entire sample, data analyzed as in Tables 4 and 5. Row B: same sample, additional adjustment for depression severity (Carroll Rating Scale). Rows C-E: analyses as in Row A, but excluding: left-handed participants (Row C: 2 patient males, 1 comparison male, 3 patient females, no comparison females); or participants receiving psychotropic medications (Row D: see Table 1); or recent regular tobacco smokers (Row E: 6 patient males, 1 comparison male, 20 patient females, 1 comparison female). All images modified identically to increase contrast between the white brain figure and its gray background.